Company Profile · Healthcare

Shanghai MicroPort MedBot Group Co Ltd

2252 · HK
Industry
Medical Devices
Exchange
HK
Country
Hong Kong
Employees
464
Website
www.medbotsurgical.com
Current Price
HK$24.46
Live · Jul 15, 2026
Fair Buy
≤ HK$10
Margin-of-safety entry
Baillie Growth Score
40/100
Weak
Intrinsic Value · Three-Tier Range Current price HK$24.46 Live · Within the fair intrinsic-value range

Composite valuation range · conservative HK$8–HK$10 / fair HK$18–HK$25 / optimistic HK$39–HK$45. At HK$24.46, Within the fair intrinsic-value range.

At publication HK$20.22 (Jul 25, 2026)

Financial snapshot
Market capHK$25.85B
Revenue (TTM)HK$551.07M
EBITDA-HK$108.47M
Profit margin-45.31%
ROE-77.29%
Forward P/E0
EPS-HK$0.11
52-week rangeHK$15.14 – HK$35.34

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

About the company

Shanghai MicroPort MedBot (Group) Co., Ltd. engages in the research and development, manufacturing, and sale of surgical robots in the People's Republic of China. The company offers Toumai laparoscopic surgical robot; Toumai single port laparoscopic surgical robot; DFVision 3D electronic laparoscope; SkyWalker orthopedic surgical robot; trans-bronchial surgical robot for natural orifice surgery; R-ONE vascular interventional robot for pan vascular surgery; and iSR'obot Mona Lisa robotic trans perineal prostate biopsy system. It is also involved in the distribution of surgical robot devices. The company was founded in 2014 and is headquartered in Shanghai, China. Shanghai MicroPort MedBot (Group) Co., Ltd. operates as a subsidiary of Shanghai Latent Artificial Intelligence Co., Ltd.

Background

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.

Research on this stock
40/100 Hold Shanghai MicroPort MedBot: Commercial Traction Is Real, but the Re-Rating Has Already Happened Shanghai MicroPort MedBot is a Chinese surgical-robotics developer whose Toumai laparoscopic platform and SkyWalker orthopedic robot have moved from clinical-trial promise into real commercial installations across more than 60 countries. FY2025 revenue rose 114.2% to RMB551.1 million with gross margin improving to 48.4% and free cash outflow shrinking sharply, and the company just guided to first-half 2026 profitability, but roughly 71% of 2025 revenue still ran through related-party sales with parent MicroPort and the stock already trades near 32 times trailing sales. Rating Hold: the commercial inflection is genuine, but at HK$20.22 the market has already re-rated the stock to price in much of that transition, leaving little margin of safety against any execution slip. Shanghai MicroPort MedBot (Group) Co., Ltd.2252 · HKMedical DevicesJul 25, 2026